Scott Kopetz, M.D., Ph.D.

Department of Colorectal Medical Oncology, Division of Cancer Medicine

About Dr. Scott Kopetz

Scott Kopetz, M.D., Ph.D., has been selected as the inaugural chair of the newly created Colorectal Medical Oncology department. The creation of the new department was approved on Aug. 5, and a national search for a chair was launched. Kopetz was selected from among a strong pool of applicants and his appointment was effective Oct. 1.

The creation of the new department within the Cancer Medicine division follows the rise in gastrointestinal and colorectal cancers. Continued growth is expected, driven by increasing referrals, rising rates of young-onset colorectal cancer, advances in screening and precision medicine and expanded multidisciplinary opportunities through the Colorectal Center.

Kopetz earned his medical degree from the Johns Hopkins School of Medicine and his Ph.D. in cancer biology from the UT MD Anderson UTHealth Houston Graduate School of Biomedical Sciences. He completed his residency in internal medicine at Duke University Medical Center and then returned to UT MD Anderson as a fellow in medical oncology.

Following the completion of his training, he joined our faculty in 2006. He rose through the academic ranks, becoming professor of Gastrointestinal Medical Oncology in 2019.

A leader in translational and clinical research, Kopetz has built a nationally recognized program focused on colorectal cancer biology, precision medicine, molecular profiling, targeted therapeutics, treatment resistance, circulating tumor DNA, liquid biopsy technologies, cancer genomics, early-onset colorectal cancer, immunotherapy and artificial intelligence applications in cancer research and care. His work has led to 460 original articles in peer-reviewed journals and his excellence was acknowledged as the holder of two endowed positions, first the Del and Dennis McCarthy Distinguished Professorship in Gastroenterology Research and more recently the Dr. M.L. “Steve” Ruben Distinguished Chair in Gastroenterology Cancer Research.

Kopetz is a dedicated educator and mentor who has contributed extensively to the development of trainees, clinician-scientists and faculty members across UT MD Anderson. His achievements have been recognized extensively, both at a local and national level.

Within UT MD Anderson, he has received the Faculty Scholar Award, Robert M. Chamberlain Distinguished Mentor Award, John Mendelsohn Lifetime Achievement Award, and Emil Frei III Award for Excellence in Translational Research within the Cancer Medicine division. His prestigious national honors include elections to the Association of American Physicians and the American Society of Clinical Investigation. He was also named a Fellow of the American Society of Clinical Oncology and is a recipient of the AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research from the American Association for Cancer Research.

In addition to his clinical and academic accomplishments, Kopetz has demonstrated exceptional leadership in several key roles, including deputy chair for Translational Research in Gastrointestinal Medical Oncology, associate vice president for Translational Integration in the Office of the Chief Scientific Officer and medical director of Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) in the Therapeutics Discovery Division.

Meet Scott Kopetz, M.D., Ph.D.

Dr. Scott Kopetz, Co-Leader of Colorectal Cancer Moon Shot

Colorectal Cancer Treatment & Research

In the News

Immunotherapy and colorectal cancer: Where we are and what’s ahead

ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Researchers identify new approach to overcome resistance to KRAS-targeted therapies

Present Title & Affiliation

Primary Appointment

Chair, Colorectal Medical Oncology, Division of Cancer Medicine, UT MD Anderson, Houston, Texas

Dual/Joint/Adjunct Appointment

Dr. M.L. "Steve" Ruben Distinguished Chair, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2009	University of Texas, Graduate School of Biomedical Sciences, Houston, Texas, US, Cancer Biology, Ph.D
2001	Johns Hopkins School of Medicine, Baltimore, Maryland, US, MD
1997	Vanderbilt University, Nashville, Tennessee, US, Biomedical Engineering/ Electrical Engineering, BE

Postgraduate Training

2004-2006	Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2001-2004	Residency, Internal Medicine, Duke University Medical Center, Durham, North Carolina

Licenses & Certifications

2004	Texas Medical Board

Experience & Service

Faculty Academic Appointments

Del and Dennis McCarthy Distinguished Professor, Gastroenterology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025

Associate Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2019

Assistant Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2012

Administrative Appointments/Responsibilities

Genetics and Gene Regulation, Program Leader, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present

Associate Vice President for Translational Integration, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present

TRACTION Medical Director, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Deputy Chair for Translational Research, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present

GI Program, Program Leader, Cancer Center Support Grant, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present

Co-Director, Graduate Program in Cancer Biology, Graduate School of Biological Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2022

Other Professional Positions

Chair, NCI Colon Task Force, Bethesda, 2017 - 2023

NRG Vice Chair, Colon Cancer, NSABP/RTOG/GOG (NRG) Cooperative Group,, Philadelphia, 2015 - Present

Senior Editor, Clinical Cancer Research AACR, Bethesda, 2014 - Present

Member, NCI Gastrointestinal Steering Committee, Bethesda, MD, 2014 - 2017

Co-Chair, Southwest Oncology Group (SWOG) Translational Sciences GI Sub-Committee, Ann Arbor, MI, 2014 - 2016

Member, SWOG - Southwest Oncology Group, Ann Arbor, MI, 2012 - Present

Co-Chair, NCI Colon Task Force, Genomics Subcommittee, Bethesda, MD, 2012 - 2016

Regular Member Graduate Faculty, Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX, 2010 - Present

Honors & Awards

2026	Giants of Cancer Care Recipient, Chicago, IL
2025	Luminary Award, Georgetown University's Ruesch Center for the Cure of Gastrointestinal Cancers
2024	Association of American Physicians (AAP) Election
2024	John Mendelsohn Lifetime Achievement, MD Anderson Cancer Center
2024	Waun Ki Hong AACR for Outstanding Achievement in Translational and Clinical Cancer, American Association for Cancer Research
2023	Fellow, American Society of Clinical Oncology
2021	President's Recognition of Faculty Excellence Award, The University of Texas MD Anderson Cancer Center
2021	Chair, American Association for Cancer Research (AACR) Colorectal Conference, American Association for Cancer Research
2020	Robert M. Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center
2019	Elected Member, American Society of Clinical Investigation (ASCI), American Society of Clinical Investigation (ASCI)
2019	Distinguished Professorship, Del and Dennis McCarthy
2019	Finalist for the Robert M. Chamberlain Distinguished Mentor Award 2017, 2018, Awardee 2019
2017	2017 Emil Frei, III Award for Excellence in Translational Research, The University of Texas MD Anderson Cancer Center
2016	Distinguished Alumnus Award, The University of Texas MD Anderson Cancer Center
2013	Division of Cancer Medicine, Mentor of the Year, The University of Texas MD Anderson Cancer Center
2013	Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
2010	Gillson Longenbaugh Foundation Award
2006	The Del and Dennis McCarthy Endowed Fellowship for Gastrointestinal Cancer Research, The University of Texas MD Anderson Cancer Center
2004	Housestaff Leadership Award Recipient, Duke University Medical Center
2003	Professionalism Award, Duke University Medical School
1998	Harold Lamport Student Research Scholarship Recipient, Johns Hopkins Medical School
1998	American Federation of Aging Research's Harvard Scholar, Johns Hopkins Medical School
1997	Summa Cum Laude, Vanderbilt University
1993	Harold Sterling Vanderbilt Scholar, Vanderbilt University

Selected Presentations & Talks

Local Presentations

2026. Live: Behind the Breakthroughs. Panelist. Houston, Texas, US.
2026. Partner Perspective: Enterprise Value and Expectations for Collaboration with a Leading Cancer Center. Celebrating the Launch of TGMH: Accelerating Next-Generation Cancer Innovation at the Texas Medical Center. Houston, Texas, US.
2026. Research Priorities and Strategic Direction. CRC Faculty Retreat. Houston, Texas, US.
2026. The Harbinger's Dilemma: cDNA in Colorectal Cancer. Department of Pathology and Laboratory Medicine Retreat. Houston, Texas, US.
2026. Translational Research and Correlative Studies for Clinical Trial. Leading Clinical Research Faculty Learning Series. Houston, Texas, US.
2026. Adaptive resistance to MAPK inhibition in colorectal cancer. Princess Margaret Cancer Centre - MD Anderson Joint Symposium.
2026. Scientific Discovery for CRC MRD - The need for bench to bedside clinical trials. MRD Day- Colorectal Cancer ctDNA Symposium: INTERCEPTing MRD Through Clinical Trials. Houston, Texas, US.
2026. Colorectal Liver Metastasis Consensus Conference. Houston, Texas, US.
2025. Identifying Areas of Clinical Impact for Computational Oncology. Joint Center for Computational Oncology (JCCO). Houston, Texas, US.
2025. Introduction to Foundry Clinical Informatics Tool for Researchers. Advisory Council of Clinical Research Leaders (ACCRL). Houston, Texas, US.
2025. DoCM Introduction to Research Opportunities Series. Houston, Texas, US.
2025. Cancer Evolution. Research Town Hall – Office of the CSO. Houston, Texas, US.
2025. Genomics and Gene Regulation (GGR). CCSG External Advisory Board. Houston, Texas, US.
2025. TRAVERSE Initiatives. Research Town Hall – Office of the CSO. Houston, Texas, US.
2025. Genomics and Gene Regulation (GGR). CCSG External Advisory Board. Houston, Texas, US.
2025. MD Anderson Cancer Center and Taiho Pharmaceutical. MDACC’s ORBIT Biologics Facility. Houston, Texas, US.
2024. James P. Allison Institute 2nd Scientific Symposium. Houston, Texas, US.
2023. CCSG GI Cancer Research Retreat. Conference. CCSG GI Cancer Research Retreat. Houston, TX, US.
2023. GI SPORE. Conference. GI SPORE. Houston, TX, US.
2023. Neoadjuvant immunotherapy and predictors of who will benefit. Conference. Neoadjuvant immunotherapy and predictors of who will benefit. Houston, TX, US.
2022. Where is the Ras-field heading?. Conference. Where is the Ras-field heading?. Houston, TX, US.
2022. Liquid Biopsy. Conference. Liquid Biopsy. Houston, TX, US.
2021. Metastatic Colorectal Cancer and Anal Cancer. Conference. Metastatic Colorectal Cancer and Anal Cancer. Houston, TX, US.
2021. Colorectal Cancer: Biology and Adjuvant Therapy. Conference. Colorectal Cancer: Biology and Adjuvant Therapy. Houston, TX, US.

Regional Presentations

2023. EPICS Global Perspectives in Gastrointestinal Malignancies in 2023. Conference. EPICS Global Perspectives in Gastrointestinal Malignancies in 2023, US.
2023. Inhibitor Early Clinical Development Advisory Board Meeting. Conference. Inhibitor Early Clinical Development Advisory Board Meeting, US.
2021. Liquid biopsy: Current practice and future perspectives. Conference. Liquid biopsy: Current practice and future perspectives, US.

National Presentations

2026. Platform Trial Model. Panelist. SITC 2026 IO-ACT Summit: PD-1xVEGF. Bethesda, Maryland, US.
2026. : BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). Poster. ASCO. Chicago, Illinois, US.
2026. Molecular Therapeutics Symposium. Detroit, Michigan, US.
2026. SU2C Catalyst®. Scientific Summit. Pasadena, California, US.
2025. Pure Cure CRC Summit. K-SPY Alliance. Miami, Florida, US.
2025. Harbinger’s Dilemma: ctDNA for Minimal Residual Disease in Colorectal Cancer. 16th Annual Ruesch Symposium. DC, Washington, US.
2025. The Harbinger’s Dilemma: ctDNA in Colorectal Cancer. 9th Advances in CRC: Controversies and Emerging Approaches Symposium. New York, New York, US.
2025. FDA – AACR Endpoints Workshop. DC, Washington, US.
2025. Targeting RAS/RAF in CRC. GI Cancers US Focus. Los Angeles, California, US.
2025. First-in-human trail of M9140, an anti-CEACAM5 antibody-drug conjugate with Exatecan payload, in patients with metastatic colorectal cancer. US Investigator Meeting for the PROCEADE PanTumor Study MS202329_0010, US.
2025. Emerging Therapeutic Approaches/Advances in Antibody Drug Conjugates in CRC. Tucson Symposium - Roche Ventana. Tucson, Arizona, US.
2025. Updates in GI Cancer. Advanced/Metastatic CRC - Targeted Therapies in CRC. Bethesda, Maryland, US.
2025. GI Spore Chapel Hill. Raleigh, North Carolina.
2024. Targeting adaptive resistance in CRC. Grand Rounds. Augusta, Georgia, US.
2024. SU2C Scientific Summit.
2023. Fight CRC EAO Think Tank Research. Nashville, Tennessee, US.
2023. 2023 Expert Advisory Board: MAPK, RAS, RAF. Boston, TX, US.
2023. Inaugural June Rogers Memorial Grand Rounds. Speaker Department of Gastrointestinal Oncology. Tampa, Florida, US.
2023. Stand up to Cancer Scientific Summit 2023. Coronado, California, US.
2023. Gastrointestinal Colorectal Cancer Core Committee. NRG Oncology Winter 2023. Orlando, Florida, US.
2022. SKCC Trainee Retreat 2022. Philadelphia, Pennsylvania, US.
2022. 4th RAS Targeted Drug Development Summit. Boston, MA, US.
2021. What’s Right For me? Personalized Treatment Options in CRC: What’s in the works in biomarkers/other treatments. Conference. AllyCon, US.
2021. Utility of Circulating Tumor DNA and Assessment of Micro-Satellite Instability in Determining Treatment and Outcomes for Gastrointestinal Malignancy. Conference. Pfizer Oncology Division of Early Drug Development. La Jolla, CA, US.

International Presentations

2026. Treatment in BRAF-mutated colon cancer. VI Latin American Symposium on Gastrointestinal Oncology (SLAGO). Santiago, CL.
2026. GI Malignancies Summit. Hamilton, US.
2025. Targeted therapy for BRAF-mutated CRC. Japanese Society of Medical Oncology Annual Meeting (JSMO2025). Tokyo, US.
2024. Management of newly diagnosed CRC: A 2024 perspective / Rational vertical and horizontal inhibitor combinations for targeting RAS / Adagrasib with EGFR MAB in G12C mutant CRC / Preemptive therapy in CRC using MRD data. 2nd Global Summit on Gastrointestinal Malignancies. Hamilton, CA.
2024. Use of circulating tumor DNA in GI cancers - Strategies for treatment of liver limited metastatic disease in colorectal cancer. 1st ASCO Direct Latam Summit. Mexico City, MX.
2023. 4th GTG Symposium. Praia do Forte, Bahia, US.
2022. The changing paradigm in immuno-oncology: the past vs future in the treatment of gastrointestinal cancers. Conference. The changing paradigm in immuno-oncology: the past vs future in the treatment of gastrointestinal cancers, IT.
2022. Minimal residual disease. Conference. Minimal residual disease, BR.
2022. Treatment Landscape for BRAF V600E-mutant mCRC (Beacon)Appropriate Treatment Line for BRAF V600E-mutant mCRC (+/ MSI-H). Conference. Treatment Landscape for BRAF V600E-mutant mCRC (Beacon)Appropriate Treatment Line for BRAF V600E-mutant mCRC (+/ MSI-H). Mendoza, AR.
2022. BRAF Mutant Tumors: Strategy and New Data. Conference. BRAF Mutant Tumors: Strategy and New Data. Barcelona, ES.
2022. WCGIC Colloquium 2: Molecular Marker Platforms. Conference. WCGIC Colloquium 2: Molecular Marker Platforms. Barcelona, ES.
2021. Session XXXIV: Impact of Precision Medicine in Gastrointestinal Oncology. Conference. Session XXXIV: Impact of Precision Medicine in Gastrointestinal Oncology, TR.
2021. Liquid Biopsy in Colorectal Cancer Clinical Practice. Conference. Scientific and Organizing Committee. Brasilia, BR.
2021. Targeting Adaptive Resistance in Colorectal Cancer. Conference. Targeting Adaptive Resistance in Colorectal Cancer. Beijing, CN.
2021. Updates and Implications of Consensus Molecular Subtyping. Conference. Updates and Implications of Consensus Molecular Subtyping, US.
2021. KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a Phase 1b study. Conference. KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a Phase 1b study, US.
2021. Updates and Implications of Consensus Molecular Subtyping. Conference. Imedex, LLC, US.

Less

Selected Publications

Peer-Reviewed Articles

Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) 39(4):285-294, 2021. e-Pub 2021. PMID: 33356422.
Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer 23(16):4578-4591, 2017. e-Pub 2017. PMID: 28400427.
Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer 48(6):820-6, 2012. e-Pub 2012. PMID: 22330318.

Professional Educational Materials

Kopetz ES. Etiology and Management of Bowel Perforation in Patients with Colorectal Cancer” Gastrointestinal Malignancies: Putting Theory Into Practice at M. D. Anderson. M. D. Anderson, 2007.

Editorials

Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men 18(19):5160-2, 2012. PMID: 22912394.

Abstracts

Osterlund E, Vetere G, Payapwattanawong S, Alfaro K, Parseghian C, Overman MJ, Shen X, YC Shen JP, Van K Morris II, Singh Raghav KP, Dasari A, Kopetz S. Minimal residual disease (MRD) trials in colorectal cancer (CRC): An overview of a heterogeneous field. 2026 ASCO Gastrointestinal Cancers Symposium 44(2), 2026. e-Pub 2026.
Takeda M, Yang Z, Theardy MS, Sorokin A, Coker O, Chen S, Vien LT, Bover L, Ying H, Kopetz S, Yao W. Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer. AACR Annual Meeting 2024 84(17), 2024. e-Pub 2024.
Singh Raghav KP, Xiao L, Lewis C, Zeller BE, Overman MJ, Huey RW, Dasari A, Chang K, Quinn K, YC Shen JP, Parseghian CM, Willis J, Ludford K, Van K Morris II, Wolff RA, Wang XS, Drusbosky L, Kopetz S. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D. 2024 ASCO Annual Meeting 42(17), 2024. e-Pub 2024.
Eluri M, Sun R, Bubie A, Alshenaifi J, Zhang N, Drusbosky L, Parseghian CM, Singh Raghav KP, Kopetz S. Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
Bahrambeigi V, Lee JJ, Branchi V, Rajapakshe KI, Xu Z, Kui N, Henry JT, Kun W, Stephens BM, Dhebat S, Hurd MW, Sun R, Yang P, Ruppin E, Wang W, Kopetz S, Maitra A, Guerrero PA. Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype. AACR Annual Meeting 2024 84(10):1719–1732, 2024. e-Pub 2024.
Chu Y, Cho KS, Khanduri I, Zhou T, Jiang J, Liu Y, Yan X, Pei G, Dai Y, Liu Y, Wang R, Jadhav AS, Hernandez S, Kadara H, Solis Soto LM, Kopetz S, Maru DM, Wang L. SpatialCS: A tool to effectively integrate histological annotations and spatial transcriptomics analysis. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Villarreal OE, Lee HM, Tran H, Machado A, Alshenaifi J, Wong CW, Coker O, Minelli R, Peoples M, Martinez AH, Fowlkes N, Kanikarla P, Lin K, Bristow C, Viale A, Marszalek JR, Shen JP, Kopetz S. ASCL2+ tumor cells modulate the response of colorectal cancer to MAPK targeting therapy. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Loree JM, Dasari A, Shaheed M, Gothwal H, Singh K, Shaheed H, Mangal R, Gothwal S, Willis J, Overman MJ, Kopetz S, Singh Raghav KP. Racial and ethnic representation and disparities on clinical guideline panels in oncology. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Mohamed AM, Cho KS, Soeung M, Anderson A, Alshenaifi J, Manyam G, Villareal O, Davis J, Norton W, Gao S, Bristow C, Carbone F, Napolitano S, Coker O, Khanduri I, Huang J, Maru DM, Pilato MD, Sun R, Wang L, Menter DG, Genovese G, Draetta G, Fowlkes N, Kopetz S. Anti-CSF1R antibody monotherapy inhibits minimal residual disease in a novel immunocompetent murine colorectal cancer metastasis model. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Lee HM, Saw AK, Morris VK, Singh AK, Napolitano S, Sorokin A, Marie PK, Coker O, Villarreal OE, Anvar NE, Rai K, Kopetz S. Elevated H3K27 trimethylation mediates adaptation to DNA demethylation in BRAFV600E-mutated colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Hornstein NJ, Wang M, Yousef A, Chowdhury S, Zeineddine F, Zeineddine M, Yousef M, You S, Gunes B, Menter D, Kopetz S, Shen JP. Cell-type-specific gene programs suggest immune and stromal drivers of relapse in colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Chowdhury S, Ahmed J, Haridas V, Hong DS, Kopetz S, Shen JP. Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Johnson CW, Terrell EM, Cook J, Shui B, O'Donoghue E, Hull S, Yang MH, Sheth S, Yaeger R, Kopetz S, Morrison DK, Haigis K. Ala59 mutants of KRAS cooperate with Nf1 loss to enhance colon tumorigenesis. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Negrao MV, Molkentine D, Paula AG, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Waters L, Briere DM, Hallin J, Blumenschein GR, Skoulidis F, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen J, Heymach JV. Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Peng DH, Tedeschi A, Herdeis L, Schaaf O, Savarese F, Rocchetti F, Popow J, Huber HJ, Wilding B, Treu M, Fuchs J, Bröeker J, Wunberg T, Schischlik F, Lipp J, Williams M, Chandler V, Deckard CE, Ramamoorthy V, Daniele JR, Kopetz S, Kim M, Gibbons DL, Vellano CP, Marszalek JR, Heffernan TP, McConnell D, Pearson M, Kraut N, Rudolph D. KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Whitehead CE, Ziemke EK, Frankowski-McGregor CL, Mumby RA, Chung J, Li J, Osher N, Coker O, Norris M, Kopetz S, Baladandayuthapani V, Hollingshead M, Verma S, Sebolt-Leopold JS. MTX-531, a first-in-class pan-PI3K inhibitor spares hyperinsulinemia yielding durable tumor regressions and resilience to adaptive resistance. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
der Pol YV, Yilma B, Morris VK, Chao C, Harris M, Guinney J, Kopetz S. Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Coker O, Sorokin A, Akhave N, Pan K, Gao F, Liu Z, Kanikarla P, Lee H, Villarreal O, Alshenaifi J, Maddalena G, Mohamed A, Prescod D, Menter D, Chowdury S, Corcoran R, Rai K, Hong D, Kopetz S. YAP-TAZ-TEAD transcriptional program is a prominent driver of acquired resistance to KRASG12C-based therapies in patients with metastatic colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Ridinger M, Marie PK, Gao F, Liu Z, Maddalena G, Menter D, Sorokin A, Smeal T, Kopetz S. The PLK1 inhibitor, onvansertib, is active as monotherapy and in combination with cetuximab in RAS wild-type colorectal cancer patient-derived xenografts. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
Parseghian CM, Lee JK, Quintanilha J, Schrock AB, Graf R, Pasquina L, Sivakumar S, Oxnard GR, Tukachinsky H, Klempner SJ, Kopetz S. Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC). 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
Uppal A, Bhutiani N, YC Shen JP, Alfaro K, Kell RJ, Yousef MM, Yousef AM, Konishi T, Holliday E, Morris VK, Dasari A, Willis J, Newhook TE, Bednarski BK, You Y, Peacock O, Messick C, Das P, Chang GJ, Kopetz S. Association of pathologic nodal status with minimal residual disease after neoadjuvant treatment and resection of locally advanced rectal cancer. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
Kasi PM, Rivero S, Aushev VN, Langer N, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Meyer JM, Sharif S, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Patient-reported outcomes from the BESPOKE CRC study. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
Kasi PM, Aushev VN, Ensor J, Langer N, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Meyer JM, Sharif S, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
Pellatt AJ, Maddalena G, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz S. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
Maddalena G, Pellatt AJ, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz S. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
Takeda M, Sorokin A, Theardy M, Coker O, Kopetz S, Ying H, Draetta G, DePinho RA, Yao W. Targeting Syndecan1 to overcome acquired resistant to KRAS inhibitor in gastrointestinal cancer. AACR 84(2), 2024.
Johnson B, Haymaker C, Morris VK, Dasari A, Higbie VS, Shen JP, Parseghian C, Morelli MP, Huey R, Lee MS, Willis J, Raghav KP, Yuan Y, Zebala J, DePinho RA, Kopetz S, Overman M. A phase I/II trial of a CXCR1/2 inhibitor in combination with anti-PD-1 for circulating tumor DNA (ctDNA) positive & refractoryRAS-mutated microsatellite stable (MSS) colorectal cancer. AACR Annual Meeting 2023 83(8), 2023. e-Pub 2023.
Sorokin A, Marie PK, Gao F, Liu Z, Menter D, Kopetz S. A novel PDX-based 2-stage screening platform can identify active drug combinations against KRAS-mutated colorectal cancer. AACR Annual Meeting 2023 83(8), 2023. e-Pub 2023.
Lee HM, Sorokin A, Marie PK, Chowdhury S, Singh A, Anderson A, Alshenaifi JY, Meric-Bernstam F, Rai K, Kopetz S. Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
Ding S, Marie PK, Zhang R, Bohn A, Moseley RM, Baro N, Brown D, Pittman K, Paduch M, Hsu D, Kopetz S, Shen X. Evaluating targeted therapy combination for refractory colorectal cancer using MicroOrganoSpheres (MOS). AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
Mohamed AM, Soeung M, Alshenaifi J, Fowlkes N, Manyam G, Davis J, Anderson A, Norton W, Deem AK, Gao S, Khanduri I, Bistow C, Carbone F, Napolitano S, Huang J, Maru DM, Menter DG, Draetta GF, Genovese G, Kopetz S. Recapitulating metastatic colorectal cancer in somatic mutation models for investigating the tumor immune microenvironment in minimal residual disease. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
Lee HM, Sorokin A, Marie PK, Chowdhury S, Singh A, Anderson A, Alshenaifi JY, Meric-Bernstam F, Rai K, Kopetz S. Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
Guo S, Cheng X, Koval A, Ji S, Liang Q, Li Y, Owen LA, Kim IK, Weinstein J, Kopetz S, Shen JP, DeAngelis MM, Chen R, Wang W. Integration with benchmark data of paired bulk and single-cell RNA sequencing data substantially improves the accuracy of bulk tissue deconvolution. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
Jiang Y, Yu K, Montierth MD, Ji S, Shin SJ, Guo S, Cao S, Tang Y, Kopetz S, Msaouel P, Wang JR, Kimmel M, Loo PV, Zhu H, Wang W. Pan-cancer analysis of intra-tumor heterogeneity in 9,116 cancers using a novel regularized likelihood model. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
Kopetz S, Cutsem EV, Kuboki Y, Johnson B, Katakabe T, He M, Archuadze S, Shen L. A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
Kopetz S, Kasper S, Rivera F, Tournigand C, Cheng Y, Deshpande P, D'Alessio D, Angelozzi NA, da Silva ABP, Segal NH. Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
Kopetz S, Yoshino T, Kim TW, Yaeger R, Desai J, Wasan HS, Cutsem EV, Maughan T, Eng C, Tie J, Elez E, Lonardi S, Zhang X, Chung C, Usari T, Nicholz T, Murphy DA, Tabernero J, Ciardiello F. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
Cohen SA, Kasi PM, Aushev VN, Hanna DL, Botta GP, Sharif S, Georgios I Laliotis MD, PhD, Sharma VR, Alqahtani A, Chandana SR, Kang S, Chakrabarti S, Somer BG, Kasi A, Dayyani F, Malla M, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
Kopetz S, Bekaii-Saab TS, Yoshino T, Chung C, Zhang X, Tabernero J. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
Lenz H, Prenen H, Cutsem EV, Kössler T, Mayol J, Trapani F, Tihy M, Rubbia-Brandt L, Toso C, Bogenrieder T, Belnoue E, Derouazi M, Kopetz S. ATP128 vaccine with ezabenlimab promotes antigen-specific immune responses in stage IV colorectal cancer in the KISIMA-01 phase 1b trial. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
Lee HM, Napolitano S, Sorokin A, Woods MN, Chowdhury S, Alshenaifi JY, Singh AK, Shen JP, Meric-Bernstam F, Rai K, Kopetz S. Bromodomain and extraterminal (BET) protein inhibition sensitize BRAFV600E colorectal cancer to standard targeted therapies. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
Lenz H, Koessler T, Oberstein P, Cutsem EV, Kim S, Fritsch R, Prenen H, Morse M, Gani D, Derouazi M, Bogenrieder T, Kopetz S. KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
Kopetz S, Bekaii-Saab TS, Yoshino T, Chung C, Zhang X, Tabernero J. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
Kopetz S, Morris VK, O'Neil B, Bridgewater JA, Graham J, Parkes EE, Saunders MP, Asken E, Goodwin L, Phillips C, Robertson J, Tilston C, Woodcock S, Cook N. A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
Kopetz S, Morris VK, Alonso-Orduña V, Garcia-Alfonso P, Reboredo M, Montes AF, Maurel J, Paez D, Reinacher-Schick AC, Höhler T, Carrasco J, Galligan BM, Manning L, Preußner L, Tureci Ö, Sahin U. A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting. J Clin Onco 2022 ASCO Annual Meeting 40(supply 16), 2022. e-Pub 2022.
Kopetz S, Murphy DA, Pu J, Yaeger R, Ciardiello F, Desai J, Cutsem EV, Wasan HS, Yoshino T, Elez E, Golden A, Zhu Z, Zhang X, Tabernero J. Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Kopetz S, Yoshino T, Kim TW, Desai J, Yaeger R, Cutsem EV, Ciardiello F, Wasan HS, Maughan T, Zhang Y, Usari T, Chung C, Zhang X, Tabernero J. BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Kopetz S, Grothey A, Yaeger R, Ciardiello F, Desai J, Kim TW, Maughan T, Cutsem EV, Wasan HS, Yoshino T, Edwards ML, Golden A, Gollerkeri A, Tabernero J. BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Johnson B, Yang D, Dada HI, Drusbosky L, Kopetz S. Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Singh Raghav KP, Ou F, Venook AP, Innocenti F, Sun R, Lenz H, Kopetz S. Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Naing A, Mamdani H, Barve MA, Johnson ML, Morgensztern D, Olszanski AJ, Wolff RA, Pant S, Chaney MF, Adebanjo T, Fan J, Kim RD, Kopetz S. Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study. J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
Negrao MV, Morelli MP, Jazaeri AA, Johnson B, Kebriaei P, Deninger D, Groot ED, Collinson-Pautz MR, Demars NA, Holland JS, Heymach J, Baffa R, Kopetz S. First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
Nusrat M, Syed MA, Katkhuda R, Parra ER, Wistuba II, Kong P, Koehne A, Dasari A, Overman MJ, Menter D, Kopetz S. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Lee MS, Zemla TJ, Ciombor KK, McRee AJ, Akce M, Dakhil SR, Jaszewski BL, Ou F, Bekaii-Saab TS, Kopetz S. A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Parseghian CM, Sanchez EV, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Singh Raghav KP, Dasari A, Kee BK, Wolff RA, YC Shen JP, Kopetz S. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. J Clin Oncol 40(suppl. 16), 2022. e-Pub 2022.
Dasari A, Abdelrahim M, Acoba JD, Alluri KC, Dragovich T, Ali Kazmi SM, Musher BL, Sun R, Wong L, You Y, Zaiden RA, Kopetz S. Minimal residual disease assessment in colorectal cancer (MiRDA-C). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Parseghian CM, Sun R, Woods MN, Napolitano S, Alshenaifi J, Willis J, Nunez SK, Sorokin A, Marie PK, Singh Raghav KP, Morris VK, YC Shen JP, Sanchez EV, Rehn M, Ang A, Troiani T, Kopetz S. Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
Morris VK, Parseghian CM, Escano M, Johnson B, Singh Raghav KP, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, Le P, Margain C, Gallup D, Tam A, Foo WC, Xiao L, Yun K, Kopetz S. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Singh Raghav KP, Kee BK, YC Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
Villarreal O, Zeineddine FA, Chacko R, Parseghian CM, Johnson B, Willis J, Lee MS, Morris VK, Dasari A, Singh Raghav KP, Overman MJ, You Y, Wang Y, Maru DM, YC Shen JP, Kopetz S. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
Kopetz S. ctDNA as a Tool to Detect Minimal Residual Disease After Surgery, 2022. e-Pub 2022.
Coker O, Sorokin A, Gale K, Gao F, Shen JP, Kwong L, Wu J, Lee HM, Woods M, Villareal O, Kopetz S. Oncogenic KRASG12C dependency in colorectal cancer. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021. e-Pub 2021.
Lee HM, Napolitano S, Morris II VK, Rai K, Shen JP, Davis JS, Maru DM, Overman MJ, Wu J, Coker O, Woods MN, Villarreal O, Kopetz S. Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC. J Clin Oncol, 2021 Gastrointestinal Cancers Symposium 39(suppl 3), 2021. e-Pub 2021.
Morris VK, Raghav PS, Dasari A, Overman MJ, Kee BK, Johnson B, Parseghian CM, Shen JP, Huey R, Raymond VM, Duose DY, Luthra R, Hong DS, Janku F, Kopetz S. Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer. J Clin Oncol, 2021 Gastrointestinal Cancers Symposium 39(suppl 3), 2021. e-Pub 2021.
Kopetz S, Grothey A, Ciardiello F, Desai J, Kim TW, Maughan T, Cutsem EV, Wasan HS, Yaeger R, Yoshino T, Gollerkeri A, Edwards M, Lizaso MR, Tabernero J. Global BRAF testing practices in metastatic colorectal cancer. J Clin Oncol 2021 Gastrointestinal Cancers Symposium 39(3_suppl), 2021. e-Pub 2021.
Morris VK, Lam M, Wang X, Overman MJ, Johnson B, Kee BK, Wolff RA, Dasari A, Zorrilla IR, Tam A, Maru DM, Kopetz S. Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy. J Clin Onco 2021 Gastrointestinal Cancers Symposium 39(3_suppl), 2021. e-Pub 2021.
Singh Raghav KP, Yoshino T, Taniguchi H, Tejpar S, Vogel A, Wainberg ZA, Yamaguchi K, Kanai M, Liu Y, Mekan S, Pudussery G, Qiu Y, Kopetz S. An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC). J Clin Onco 2021 Gastrointestinal Cancers Symposium 39((suppl 3), 2021. e-Pub 2021.
Lee HM, Napolitano S, Morris VK, Rai K, YC Shen JP, Davis JS, Maru DM, Overman MJ, Wu J, Coker O, Woods MN, Villarreal O, Kopetz S. Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC. J Clin Onco 2021 Gastrointestinal Cancers Symposium 39(suppl. 3), 2021. e-Pub 2021.
C-F C, Y-M Y, K-H Y, Desai J, Price TJ, Tebbutt N, Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Gollerkeri A, Maharry K, Kopetz S. Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). Annals of Oncology 31(S6):S1276, 2020. e-Pub 2020.
Parikh A, Gugel EG, Smolyakova N, M-H J, Toms N, Lin Y, Kim JS, Kopetz S. A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing. Annals of Oncology 31(S4):S435, 2020. e-Pub 2020.
Davis JS, Kanikarla P, Yu PL, Gagea M, Fang D, Sebastian M, Yang P, Hawk E, Dashwood R, Lichtenberger LM, Menter D, Kopetz S. Sulindac plus phospholipid is effective for polyp reduction and safer than sulindac alone. Cancer Res 2020 American Association for Cancer Research 80(suppl 16), 2020. e-Pub 2020.
A GrotheyKopetz S, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Maharry K, Christy-Bittel J, Gollerkeri A, Tabernero J. Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. Annals of Oncology 31(S3):S243, 2020. e-Pub 2020.
Korphaisarn K, Lam M, Loree JM, Ruiz E, Aguiar S, Kopetz S. Consensus molecular subtypes in colorectal cancer differ by geographic region. J Clin Oncol, 2020 ASCO Virtual Scientific Program 38(15_suppl), 2020. e-Pub 2020.
Sarshekeh AM, Roszik J, Manyam GC, Advani SM, Willis J, Shen JP, Morris J, Davis JS, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A mutation to define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer. J Clin Oncol, 2020 Gastrointestinal Cancers Symposium 38(suppl 4), 2020. e-Pub 2020.
Tabernero J, Grothey A, Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, García-Alfonso P, Gollerkeri A, Pickard M, Maharry K, Christy-Bittel J, Anderson L, Kopetz S. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Annals of Oncology 30(Supplement 5), 2019. e-Pub 2019.
Napolitano S, Carbone F, Menter DG, Troiani T, Genovese G, Kopetz S. Immune competent somatic mosaic model of colorectal cancer. Annals of Oncology 30(Supplement 5), 2019. e-Pub 2019.
Tabernor J, Grothey A, Van Cutsem E, Yaeger R, Harpreet W, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren T, Arkenau H, Garcia-Alfonsi P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, S|| K. Encorafenib plus Cetuximab as a New Standard of Care for Previously-Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses, 2019. e-Pub 2019.
Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Gollerkeri A, Maharry K, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, Garcıa Alfonso P, Sandor V, Christy-Bittel J, Anderson L, Tabernero J. BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. Annals of Oncology 30(Suppl 4):iv154, 2019. e-Pub 2019.
Johnson B, Loree JM, Morris VK, Dasari A, Pant S, Raghav KPS, Kopetz S. Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer. J Clin Oncol 37(Suppl 4; abstr 596), 2019. e-Pub 2019.
Singh Raghav KP, Yaeger R, Loree JM, Dasari A, Morris VK, Kee BK, Raymond VM, Nagy RJ, Lanman RB, Strickler JH, Corcoran RB, Overman MJ, Kopetz S. Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). J Clin Oncol 37(suppl 4; abstr 604), 2019. e-Pub 2019.
Henry J, Loree JM, Strickler JH, Singh Raghav KP, Morris VK, Raymond VM, Lanman RB, Yaeger R, Corcoran RB, Overman MJ, Kopetz S. Quantifying the evolution of tumor architecture using serial circulating tumor DNA. J Clin Oncol 37(suppl 4; abstr 600), 2019. e-Pub 2019.
Kopetz S, Grothey A, Yaeger R, Cuyle PA, Huijberts S, M Schellens JH, Elez E, Fakih M, Viladot CM, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan HS, Maharry K, Christy-Bittel J, Gollerkeri A, Cutsem EV, Tabernero J. Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 37(suppl 4; abstr 688), 2019. e-Pub 2019.
Loree JM, Dowers A, Tu D, O'Callaghan CJ, Edelstein D, Quinn H, Jonker DJ, Karapetis C, Price TJ, Zalcberg JR, Moore MJ, Waring PM, Kennecke HF, Hamilton SR, Kopetz S. Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial. J Clin Oncol 37(suppl 4; abstr 537), 2019. e-Pub 2019.
Overman MJ, Lonardi S, Mark Wong KY, Lenz H, Gelsomino F, Aglietta M, Morse M, Cutsem EV, McDermott RS, Hill AG, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Atasoy A, Zhao H, Lei M, Kopetz S. Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. J Clin Oncol 37(suppl 4; abstr 635), 2019. e-Pub 2019.
Overman MJ, Jaimovich A, Kennedy D, Tan M, Gavino D, Mortimer S, Chudova D, Talasaz AA, Odegaard J, Kopetz S. A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype.. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
Parseghian CM, Loree JM, Morris VK, Pereira AAL, Vilar Sanchez E, Kee BK, Raghav KPS, Dasari A, Wu J, Raymond VM, Banks K, Talasaz AA, Lanman RB, Overman MJ, Kopetz S. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
Pereira AAL, Lam M, Kanikarla Marie P, Raghav KPS, Morris VK, Brown H, Windham J, Duose DY, Overman MJ, Vilar Sanchez E, Wistuba II, Kipp P, Janku F, Sinha S, Kopetz S. Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
Nusrat M, Oh J, Jiang ZQ, Dasari A, Fogelman DR, Kee BK, Menter D, Raghav KPS, Morris VK, Wu J, Meric-Bernstam F, Morris J, Overman MJ, Kopetz S. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
Sarshekeh AM, Loree JM, Manyam GC, Pereira AAL, Raghav KPS, Lam M, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The characteristics of ARID1A mutations in colorectal cancer. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
Lam M, Pereira AAL, Marie PK, Davis JS, Yu RX, Morris J, Manyam GC, Broom BM, Maru DM, Katkhuda R, Menter D, Kopetz S. Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC). J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
Loree JM, Strickler JH, Lima Pereira AA, Lam M, Raghav KPS, Morris VK, Menter D, Banks K, Nagy RJ, Raymond V, Overman MJ, Talasaz AA, Lanman RB, Kopetz S. Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Overman MJ, Kopetz S. Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Raghav KPS, Loree JM, Morris J, Manuel S, Crosby S, Meric-Bernstam F, Menter D, Raymond V, Lanman RB, Talasaz AA, Kopetz S. Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC). 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Willauer AN, Loree JM, Lima Pereira AA, Lam M, Raghav KPS, Morris VK, Menter D, Shaw KR, Broaddus R, Meric-Bernstam F, Wang Y, Overman MJ, Kopetz S. Clinical and molecular characterization of early-onset colorectal cancer patients with inflammatory bowel disease. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Willis J, Morelli MP, Morris VK, Loree J, Lam M, Lima Pereira AA, Raghav KPS, Kee BK, Vilar Sanchez E, Eng C, Manuel S, Crosby S, Wolff RA, Lanman RB, Talasaz AA, Janku F, Overman MJ, Kopetz S. Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC). 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Lima Pereira AA, Loree JM, Davis JS, Lam M, Morris VK, Overman MJ, Raghav KPS, Kee BK, Fogelman DR, Vilar Sanchez E, Shureiqi I, Eng C, Manuel S, Crosby S, Wolff RA, Lanman RB, Talasaz AA, Janku F, Kopetz S. Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Lam M, Lima Pereira AA, Loree JM, Advani SM, Overman MJ, Bailey A, Johnson A, Holla VK, Sanchez NS, Khotskaya Y, Meric-Bernstam F, Kopetz S. Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Kopetz S, Spira AI, Wertheim M, Kim E, Tan BR, Lenz HJ, Nikolinakos P, Rich P, Smith DA, Helwig C, Dussault I, Ojalvo L, Gulley JL. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Mehrvarz Sarshekeh A, Loree J, Lima Pereira AA, Raghav KPS, Lam M, Advani SM, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The rate of novel actionable mutations in standard of care NGS panel testing in gastrointestinal malignancies. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
Kopetz S, Spira, AI, Wertheim M, Kim E, Tan BR, Lenz HJ. A bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. Journal of Clinical Oncology 36(4suppl):764, 2018. e-Pub 2018.
Kopetz S, Zagonel V, Overman MJ, McDermott R, Morse MA, Chen FL, Lee J, Moss RA, Ling L, Greenfield A, Greenawalt D, Cao ZA. Microbiome Analyses in Patients with Previously Treated, Deficient DNA Mismatch Repair/Microsatellite Instability-High Metastatic Colorectal Cancer Treated with Nivolumab +/- Ipilimumab: CheckMate 142, Bristol Myers Squibb, 2017. e-Pub 2017.
Morris V, Sorokin A, Blum M, Korphaisarn K, Estrella J, Faoro L, Wang M, Hamilton S, Kapoun AM, Kopetz S. RSPO3 overexpression is a characteristic feature of signet ring gastrointestinal malignancies 17(1S), 2017. e-Pub 2017.
Andre T, Overman MJ, Lonardi S, Aglietta M, McDermott R, Wong KYM, Morse M, Hendlisz A, Moss RA, J-M L, Tang H, Cao ZA, Kopetz S. Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) 1 ipilimumab (IPI): CheckMate 142. Annals of Oncology 28(Suppl 5, v163), 2017. e-Pub 2017.
Kopetz S, McDonough SL, Morris II VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz Jr LA, Joseph Allegra C, Wang SE, Hanyoung Lieu C, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie KA, Hochster HS. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). 2017 Gastrointestinal Cancers Symposium 35(suppl), 2017. e-Pub 2017.
Kopetz S, Lonardi S, McDermott RS, Aglietta M, Hendlisz A, Morse M, Leach JW, Neyns B, Chan E, Chen F, Wong KYM, Lee JJ, Garcia-Alfonso P, Hill AG, Lenz HJ, Desai J, Moss RA, Cao ZA, Overman MJ, Andre T. Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
Loree JM, Miron B, Holla V, Overman MJ, Lima Pereira AA, Lam M, Morris VK, Raghav KPS, Routbort M, Shaw KR, Burck N, Sharivkin R, Edelheit O, Meric-Bernstam F, Vidne M, Tarcic G, Kopetz S. Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
Overman MJ, Vauthey JN, Aloia TM, Conrad C, Chun YS, Lima Pereira AA, Jiang Z, Crosby S, Wei S, Raghav KPS, Morris VK, Tan M, Maslan A, Talasaz AA, Mortimer S, Kopetz S. Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
Nusrat M, Manyam GC, Loree JM, Lam M, Overman MJ, Maru DM, Routbort M, Morris J, Kopetz S. Molecular characterization of TP53 mutations and copy number change in colorectal cancers, 2017. e-Pub 2017.
Korphaisarn K, Chou CK, Xia W, Clarke C, Davis JS, Liao HW, Crosby S, Manuel S, Wu J, Menter D, Hung CM, Kopetz S. Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents, 2017. e-Pub 2017.
Loree JM, Korphaisarn KK, Lam M, Morris VK, Raghav KP, Overman MJ, Eng C, Dasar A, Kee BK, Fogelman D, Wolff RA, Shaw K, Broaddus R, Routbort MJ, Luthra R, Maru DM, Menter DG, Meric-Bernstam F, Kopetz S. APCWT/RASWT/BRAFWT tumors represent an under recognized poor prognostic group of right sided colorectal cancer 77(13S), 2017. e-Pub 2017.
Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Shureiqui I, Kee BK, Wolff RA, Eng C, Menter D, Hamilton SR, Dasari A, Raghav KPS, Mehta TR, Manuel S, Kopetz S. Signet ring cell colorectal cancer: Genomic insights into a rare subpopulation of colorectal adenocarcinoma. J Clin Oncol 35(suppl 4s), 2017. e-Pub 2017.
Strickler JH, Banks KC, Nagy RJ, Lanman RB, Talasaz AA, Corcoran RB, Kopetz S. Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC). J Clin Oncol 35(suppl 4S), 2017. e-Pub 2017.
Loree JM, Lam M, Morris J, Overman MJ, Raghav KPS, Eng C, Dasari A, Kee BK, Fogelman DR, Wolff RA, Jiang Z, Davis JS, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Menter D, Meric-Bernstam F, Kopetz S. RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. J Clin Oncol 35(suppl 4S), 2017. e-Pub 2017.
Morris VK, Wu J, Adam L, Tian F, Gagea M, Hong DS, Menter D, Kopetz S. Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer. J Clin Oncol 34(suppl 4S), 2016. e-Pub 2016.
Clarke C, Korphaisarn K, Jiang Z, Crosby S, Davis DW, Wu W, Raghav KPS, Overman MJ, Morris VK, Kee BK, Eng C, Fogelman DR, Navin N, Kopetz S. Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer. J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
Dasari A, Overman MJ, Fogelman DR, Kee BK, Menter D, Raghav KPS, Morris VK, Oh J, Wu J, Jiang Z, Tian F, Adam L, Brimer M, Morris J, Meric-Bernstam F, Kopetz S. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC). J Clin Oncol 34(suppl), 2016. e-Pub 2016.
Raghav KPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shanmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 34(suppl), 2016. e-Pub 2016.
Lee MS, Advani SM, Morris J, Jiang ZQ, Manyam GC, Menter D, McIntosh Broom B, Eng C, Overman MJ, Maru DM, Hamilton SR, Kopetz S. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
Kopetz S. Opportunities for integration of PDX models into clinical trials, 2016. e-Pub 2016.
Sarshekeh AM, Overman MJ, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Manuel S, Shureiqui I, Wolff RA, Patel K, Luthra R, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. J Clin Oncol 34(suppl 4S), 2016. e-Pub 2016.
Morris V, Janku F, Huang H, Fu S, Overman M, Piha-Paul S, Subbiah V, Kee B, Tsimbierdou A, Fogelman D, Shurieqi I, Manuel S, Scamardo A, Lanman R, Sommer N, Hong D, Kopetz S. Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer 14(12S2), 2015. e-Pub 2015.
Davis JS, Advani S, Banfield E, Overman M, Jiang ZQ, Manuel S, Daniel C, Chang S, Kopetz S. Demographics of colorectal cancer patients vary by aspirin use 75(15S), 2015. e-Pub 2015.
Morelli MP, Overman M, Vilar E, Morris V, Fogelman D, Shureiqi I, Garret C, Kanwal R, Eng C, Kee B, Manuel S, Wolff R, Sebisanovic D, Sew L, Zapanta A, Shiller B, Mei G, Eltoukhy H, Talasaz AA, Kopetz S. Prospective clinical application of circulating cell-free DNA sequencing in metastatic colorectal cancer 75(15S), 2015. e-Pub 2015.
Advani SM, Lee MS, Overman MJ, Fogelman D, Kee BK, Manuel SD, Davis J, Morris VK, Clarke CN, Daniel CR, Menter DG, Hamilton SR, Maru DM, Kopetz S. Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients 75(15S), 2015. e-Pub 2015.
Kopetz S, McDonough S, Morris VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, Lieu CH, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie K, Hochster HS. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
Morris VK, James B, Tian F, Jiang ZQ, Overman MJ, Maru DM, Menter D, Powis G, Kopetz S. Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC). J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
Raghav KPS, Tang C, Morelli MP, Amin HM, Chen K, Manyam GC, Broom BM, Talasaz A, Overman MJ, Shaw KR, Meric-Bernstam F, Maru DM, Eng C, Hong DS, Kopetz S. Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC). J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
Clarke C, Lee MS, Manyam GC, Jiang ZQ, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Raghav KPS, Eng C, Chang GJ, Overman MJ, Maru DM, Kopetz S. Proteomic features of colorectal cancer independently predict relapse-free survival. J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
Lee MS, Clarke C, Jiang ZQ, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
Overman MJ, Kee BK, Fogelman DR, Eng C, Vilar Sanchez E, Shroff RT, Dasari A, Wolff RA, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
Morelli MP, Overman MJ, Kee BK, Vilar Sanchez E, Morris VK, Fogelman DR, Janku F, Garrett CR, Shureiqi I, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Predictors of clonal evolution in metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
Lee MS, Clarke C, Jiang Z, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
Morris VK, Morelli MP, Janku F, Overman MJ, Kee BK, Fogelman DR, Vilar Sanchez E, Shureiqi I, Garrett CR, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
Shah MS, Fogelman DR, Daniel-MacDougall C, Raghav KPS, Heymach J, Tran HT, Jiang Z, Kopetz S. Il-8 as an underutilized prognostic factor in metastatic colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
Overman MJ, Eng C, Kee BK, Fogelman DR, Shroff RT, Fark C, Moinova H, Lutterbaugh J, Issa JJ, Markowitz SD, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
Lee MS, Lieu CH, Overman MJ, Eng C, Morris J, Jiang Z, Morelli MP, Heymach J, Tran HT, Kopetz S. Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
Conte B, George B, Dasari A, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz S. Colorectal high-grade neuroendocrine carcinoma: A single institution experience. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
Pereira AAL, De Mendonga Rego FJ, Morris VK, Overman MJ, Eng C, Garrett CR, Ferrarotto R, Lee MS, Jiang Z, Hoff PM, Vauthey J, Vilar Sanchez E, Maru DM, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
Morelli MP, Overman MJ, Vilar Sanchez E, Morris VK, Shureiqi I, Garrett CR, Fogelman DR, Raghav KPS, Kee BK, Deaton L, Eng C, Wolff RA, Sebisanovic D, Siew L, Zapanta A, Mei G, Schiller B, Eltoukhy H, Talasaz AA, Kopetz S. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients 32(5s), 2014. e-Pub 2014.
Lee MS, Overman MJ, Maru DM, Jiang Z, Manuel S, Eng C, Kee BK, Fogelman DR, Garrett CR, Advani SM, Sanchez EV, Shureiqi I, Wolff RA, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer 32(5s), 2014. e-Pub 2014.
Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC) 32(5s), 2014. e-Pub 2014.
Corcoran RB, Atreya CE, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan D, Kurzrock R, Sun P, Cunningham EA, Orford KW, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis 32(5s), 2014. e-Pub 2014.
Hong DS, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, Zinner R, Fogelman DR, Mistry R, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer 32(5s), 2014. e-Pub 2014.
Kopetz S, Jiang Z, Overman MJ, Dreezen C, Tian S, Li Y, Simon I, Chang GJ, Maru DM. Genomic classifiers (ColoPrint/MSI-Print) predict outcome and chemotherapy benefit in stage II and III colon cancer patients. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
Lieu CH, Varella-Garcia M, Xu LG, Jiang Z, Eckhardt SG, Messersmith WA, Maru DM, Kopetz S. Increased gene copy number and amplification of FGF2 and FGFR1 in metastatic colorectal cancer. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
Raghav KPS, Wang W, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
Jiang Z, Deaton L, Neishaboori N, Vauthey JN, Overman MJ, Maru DM, Kopetz S. Molecular characteristics of complete PTEN loss in metastatic colorectal cancer. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
Morris VK, Overman MJ, Maru DM, Kopetz S. Progression-free survival in metastatic, BRAF-mutated colorectal cancer. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
Morris VK, Overman MJ, Eng C, Vilar Sanchez E, Morelli MP, Jiang Z, Luthra R, Maru DM, Meric-Bernstam F, Kopetz S. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
Kopetz S, Jiang Z, Overman MJ, Rosenberg R, Salazar R, Tabernero J, Stork L, Li Y, Simon I, Chang GJ, Maru DM. Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Vilar Sanchez E, Eng C, Kee BK, Deaton L, Garrett CR, Diehl F, Angenendt P, Kopetz S. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
Chen Z, Overman MJ, Garrett CR, Jiang ZQ, Wolff RA, Abbruzzese JL, Eng C, Kopetz S. Systematic survey of therapeutic trials for metastatic colorectal cancer. J Clin Oncol 30(suppl 4), 2012. e-Pub 2012.
Overman MJ, George B, Kalil K, Ferrarotto R, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S. Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly. J Clin Oncol 30(Suppl 4), 2012. e-Pub 2012.
Shah NN, Lieu CH, Ivan C, Overman MJ, Shimizu M, Morris J, Tran HT, Heymach J, Calin G, Kopetz S. Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients. J Clin Oncol 30(suppl 4), 2012. e-Pub 2012.
Overman MJ, Eng C, Kee BK, Fogelman DR, Fark C, Hippert R, Holter S, Issa JP, Hamilton SR, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer 30, 2012. e-Pub 2012.
Chen ZY, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong DS, Hoff PM, Tran HT, Heymach J, Overman MJ, Kopetz S. Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer 30, 2012. e-Pub 2012.
Shah NN, Lieu CH, Ivan C, Overman MJ, Shimizu M, Morris J, Tran H, Heymach J, Calin G, Kopetz S. Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients, 2012. e-Pub 2012.
Mao M, Tsao L, Dayyani F, Gopal V, Nanda Y, Mills G, Bollag G, Davies M, Gallick G, Kopetz S. Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation:LB-228, 2011. e-Pub 2011.
Lieu CH, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 401)), 2011. e-Pub 2011.
Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru M, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. J Clin Oncol 29((suppl 4; abstr 399)), 2011. e-Pub 2011.
Kopetz S, Tran HT, Cunningham D, Mookerjee B, Pike L, Jurgensmeier J, Heymach J. Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 406)), 2011. e-Pub 2011.
Lieu CJ, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer 29, 2011. e-Pub 2011.
George B, Estrella J, Machado L, Ferrarotto R, Hoff PM, Rashid A, Kopetz S. High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis 29, 2011. e-Pub 2011.
Lieu CH, Tran HT, Jiang Z, Mao M, Overman MJ, Eng C, Morris J, Ellis LM, Heymach J, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer 29, 2011. e-Pub 2011.
Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru D, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer 29, 2011. e-Pub 2011.
Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, Nolop KB, Bhattacharya S, Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors, 2010. e-Pub 2010.
Kopetz S, Hoff P, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab:292, 2009. e-Pub 2009.
Sankhala K, Takimoto C, Mita A, Xiong H, Rodon JA, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S. Two Phase I, Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules, 2008. e-Pub 2008.
Kopetz S, Wolff R, Eng C, Henry L, Glover K, Chang D, Overman M, Gallick G, Abbruzzese J. Phase IB study of Src inhibitation with dasatinib in combination with 5-fluorouracil, leuvocorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer:LB-69, 2008. e-Pub 2008.
Kopetz S, Mita MM, Sankhala KK, Moseley J, Sherman BM, Bradley CR, Tolcher AW. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors, 2008. e-Pub 2008.
Politano S, Pathak P, Hoff PM, Charnsangavej C, Overman MJ, Loyer E, Vauthey J, Wallace MJ, Wolff RA, Kopetz S. The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia, 2008. e-Pub 2008.
Kopetz S, Shah AN, Gallick GE. Src Continues Aging: Current and Future Clinical Directions:7232, 2007. e-Pub 2007.
Kopetz S, Wu J, Davies M, Parikh N, Johnson F, Gallick G, Donato N. Synergistic activity of Src and EGFR inhibitors in colon cancer, 2007. e-Pub 2007.
Kopetz S. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer, 2007. e-Pub 2007.
Kopetz S, Wu J, Davies M, Johnson F, Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer, 2007. e-Pub 2007.
Kopetz S, Wu J, Johnson F, Donato N. Anti-tumor effects of combination therapy with anti-EGFR and anti-Src therapy in colorectal cancer:B51, 2006. e-Pub 2006.
Kopetz S, Dang J, Overman M, Phan L, Feig B, Patel D, Wolff RA, Eng CA, Abbruzzese JL, Hoff P. Bevacizumab toxicity and efficacy are unaffected by regimen or resection status: A single institution retrospective study, 2006. e-Pub 2006.
Kopetz S. Minimal Residual Disease Detection and Intervention: Challenges and Opportunities. 2024 ASCO Annual Meeting.
Shah PK, Aushev VN, Ensor J, Sanchez SA, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Liu MC, Jurdi AA, Aleshin A, Meyer JM, Sharif S, Kopetz S. Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
Yaeger R, Uboha NV, Klempner SJ, Bekaii-Saab TS, Sabari JK, Barve MA, Saltzman JN, Peguero JA, Paulson AS, Jänne PA, Pelster M, Cruz-Correa M, Kim AMK, Hu N, Ahmad HA, Kopetz S. Adagrasib (Ada) + cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
Maddalena G, Perissinotto E, Intini R, Morris V, Bergamo F, Newhook T, Lonardi S, Kopetz S. Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer. 2025 ASCO Gastrointestinal Cancers Symposium.
Morris V, Quintanilha J, Elvin J, Graf R, Kopetz S. Clinical relevance of tumor fraction assessment from circulating tumor DNA in metastatic colorectal cancer. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
Vetere G, Sun R, Van K Morris II, Dasari A, Kee BK, YC Shen JP, Willis J, Morelli MP, Sorokin A, Marie PK, Wolff RA, Overman MJ, Singh Raghav KP, Sanchez EV, Huey RW, Higbie V, Le P, Baig Y, Kopetz S, Parseghian C. Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC). 2025 ASCO Annual Meeting 43(16).
Osterlund E, Maddalena G, Pellatt AJ, Eluri M, Parseghian C, Aziz K, Alfaro K, Kell RJ, Manyam GC, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Dasari A, Maitra A, Van K Morris II, Kopetz S. Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study. 2025 ASCO Annual Meeting 43(16).
Bent AH, Parseghian C, Morris VK, Kee BK, Huey RW, Morelli MP, Shen JP, Jernigan K, Fernandez A, Harrison C, Horodecky K, Dasari A, Alfaro K, Aziz K, Kell RJ, Kopetz S. DAILY: A prospective single arm study evaluating the impact of vitamin D, aspirin, exercise, and diet in colorectal cancer patients with ctDNA-defined minimal residual disease. 2025 ASCO Annual Meeting 43(16).
Dasari A, Mazard T, Cohen R, Elez E, Tarazona N, Borg C, Rinaudo P, Chêne L, Fagerberg J, Schmoll HJ, Cervantes A, Tabernero J, Kopetz S. Survival of patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal carcinoma (mCRC) treated with EO4010 + nivolumab (EO/N). 2025 ASCO Annual Meeting 43(16).
Elez E, Yoshino T, Shen L, Lonardi S, Cutsem EV, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Van K Morris II, Wu C, Usari T, Laliberte RJ, Dychter SS, Zhang X, Tabernero J, Kopetz S. First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. 2025 ASCO Annual Meeting 43(17).
Osterlund E, Maddalena G, Pellatt AJ, Vetere G, Eluri M, Parseghian C, Aziz KE, Alfaro K, Kell RJ, Konishi T, Overman MJ, Morelli MP, Willis J, Shen J, Raghav K, Newhook T, Shen X, Morris V, Dasari NA, Kopetz S. Circulating tumor DNA (ctDNA) clearance and correlation with outcome in the INTERCEPT colorectal cancer (CRC) study. 2025 ESMO Congress 36(2).
Kopetz S, Garcia-Carbonero R, Han S, Rivera II, Rodriguez JC, Boni V, Vieito M, Miguel MJ, Pallis AG, Habermehl C, Siddiqui A, Kato K. Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer: updated clinical data from the Phase 1 PROCEADE-CRC-01 study. 2025 ESMO Congress 36(2).
Payapwattanawong S, Osterlund E, Vetere G, Bent AH, Dasari A, Kee BK, Parseghian C, Willis J, YC Shen JP, Singh Raghav KP, Eluri M, Morelli MP, Overman MJ, Le P, Huey RW, Martinez SA, Higbie V, Shen X, Van K Morris II, Kopetz S. Aspirin use and PI3K mutations in metastatic colorectal cancer (mCRC). 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
Kopetz S, Tabernero J, Lonardi S, Shen L, Wasan HS, Yoshino T, Cutsem EV, Kim TW, Eng C, Ciardiello F, Desai J, Maughan T, Yaeger R, Usari T, Zhang X, Beyzarov E, Mori A, Whalley E, Zhang X, Elez E. BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). American Society of Clinical Oncology.
Kopetz S, Shah KN, Yoshino T, Yaeger R, Eng C, Cutsem E, Wasan HS, Desai J, Ciardiello F, Maughan TS, Kim TW, Fernandez E, Tie J, Takiya L, Rosenthal S, Saul M, Hamilton P, Whalley E, Zhang X, Tabernero J. 7R0 Molecular correlates of enhanced outcome with first-line (1L) encorafenib + cetuximab (EC) ± mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BREAKWATER study. ESMO Gastrointestinal Cancers Congress 2026.

Book Chapters

Yu, IS, Advani, S, Kopetz, S. Initial Systemic Chemotherapy for Metastatic Colorectal Cancer, 279-286, 2022.
Dasari A, Johnson B, Parseghian C, Raghav K, Kopetz S. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. 3rd, 2020.
Kopetz S. Targeted Therapy in Cancer. In: Targeted Therapy for Colorectal Cancer. Humana Press, 101-24, 2008.
Hoff PMG, Kopetz S. Systemic Therapy for Non-operable Colorectal Cancer Metastases. In: Liver Metastases. Springer, 51-8, 2008.
Kopetz S, Raber M, Abbruzzese J. Colorectal, Anal, and Unknown Primary Cancer (electronic web update). In: Cancer Medicine, 2006.
Kopetz S, Hoff P. Management Issues in Patients Presenting with Stage IV Colorectal Cancer. In: Advanced Therapy in Surgical Oncology. Decker Press, 281-91, 2006.

Less

CV information above last modified October 20, 2026

Scott Kopetz, M.D., Ph.D.

About Dr. Scott Kopetz

In the News

Immunotherapy and colorectal cancer: Where we are and what’s ahead

ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Researchers identify new approach to overcome resistance to KRAS-targeted therapies

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Honors & Awards

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Selected Publications

Peer-Reviewed Articles

Professional Educational Materials

Editorials

Abstracts

Book Chapters

Patient Reviews

Related Links

Kopetz Laboratory

Gastrointestinal Medical Oncology department

Cancer Medicine division

Help #EndCancer

Scott Kopetz, M.D., Ph.D.

About Dr. Scott Kopetz

In the News

Immunotherapy and colorectal cancer: Where we are and what’s ahead

ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Researchers identify new approach to overcome resistance to KRAS-targeted therapies

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Honors & Awards

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Selected Publications

Peer-Reviewed Articles

Professional Educational Materials

Editorials

Abstracts

Book Chapters

Patient Reviews

Request an Appointment

Related Links

Kopetz Laboratory

Gastrointestinal Medical Oncology department

Cancer Medicine division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson